

1 **THE STATE OF CURRENT MANAGEMENT OF THE HEIGHTENED RISK FOR**
2 **ATHEROSCLEROTIC CARDIOVASCULAR EVENTS IN AN ESTABLISHED**
3 **COHORT OF PATIENTS WITH LUPUS ERYTHEMATOSUS**

4 Megan Zhao, BA^{1,2}, Rui Feng, PhD³, Victoria P. Werth, MD^{1,2*}, Kevin Jon Williams, MD^{4*‡}

5
6 ¹Corporal Michael J. Crescenz Veterans' Administration Medical Center, Philadelphia, PA, USA

7 ²Department of Dermatology, University of Pennsylvania, Perelman School of Medicine,
8 Philadelphia, PA

9 ³Department of Biostatistics, University of Pennsylvania, Perelman School of Medicine,
10 Philadelphia, PA

11 ⁴Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of
12 Medicine at Temple University, Philadelphia, PA, USA

13 *Co-senior authors

14
15
16 ORCIDs

17 MZ: 0000-0002-8005-9111

18 RF: 0000-0003-4151-7228

19 VPW: 0000-0003-3030-5369

20 KJW: 0000-0002-0000-2159

21
22
23
24
25
26 ‡To whom correspondence should be addressed:

27 Kevin Jon Williams, MD

28 Professor of Cardiovascular Sciences, Professor of Medicine

29 Lewis Katz School of Medicine at Temple University

30 Medical Research Building (MRB)

31 3420 North Broad Street, Room 220

32 Philadelphia PA 19140

33 USA

34 eMAIL: kjwilliams@temple.edu

39 **Abstract**

40 **Background:** Patients with lupus erythematosus (LE) are at a heightened risk for clinical events,
41 chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD). We
42 recently proposed new guidelines to categorize levels of risk for future ASCVD events
43 specifically in LE patients, with recommendations for management. Here, we assessed the state
44 of current management of ASCVD event risk in light of these new recommendations.

45 **Methods:** We studied our entire UPenn Longitudinal Lupus Cohort of patients with cutaneous
46 LE, without or with concurrent systemic LE, for whom we had full access to medical records
47 (n=370, LE-ASCVD Study Cohort, years 2007-2021).

48 **Results:** Of our LE-ASCVD Study Cohort, 336/370 (90.8%) had a designated primary-care
49 physician. By the new guidelines, the most recent plasma LDL cholesterol levels were above
50 goal for 252/370 (68.1%) of the Cohort. Two hundred sixty-six (71.9%) had hypertension, which
51 was under- or un-treated in 198/266 (74.4%). Of current smokers, 51/63 (81.0%) had no
52 documented smoking cessation counseling or referrals. Diabetes was generally well-managed,
53 and hypertriglyceridemia was uncommon. Of the Cohort, 254 patients qualified for two widely
54 used online calculators in primary prevention that estimate the risk of an ASCVD event in the
55 next 10 years: the ACC-ASCVD Risk Estimator Plus and QRisk3. We also stratified these 254
56 patients into the categories of ASCVD event risk we recently defined specifically for LE.
57 Surprisingly, these three methods for estimating ASCVD event risk showed clinically
58 meaningful agreement for only 100/254 (39.4%), i.e., discordance for over 60% that could affect
59 clinical management. The documented rate of ASCVD events in the first 10 years after
60 enrollment was 22.3% (95% CI 16.9%, 27.4%), indicating a high-risk population despite a
61 preponderance of women and a median age at enrollment of only 47 years.

62 **Conclusion:** Cutaneous LE patients are under-treated compared with the new guidelines and,
63 accordingly, they experience a substantial burden of ASCVD events. Moreover, it is unclear how
64 to accurately assess future ASCVD event risk in these patients – except that it is high – and this
65 uncertainty may complicate clinical management. Efforts are underway to improve ASCVD
66 event risk estimation and guideline implementation in lupus patients.

67 **Keywords:** atherosclerotic cardiovascular disease, lupus erythematosus, guidelines

68

69 **Introduction**

70 Patients with lupus erythematosus (LE) suffer from a heightened risk of clinical events,
71 chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD).
72 Several clinical features of LE contribute to the problem.^[1] First, patients with LE exhibit an
73 increased prevalence of conventional risk factors for ASCVD events, particularly
74 dyslipoproteinemia and hypertension, and glucocorticoid use often exacerbates additional
75 conditions related to cardiovascular risk, such as obesity, the metabolic syndrome, so-called
76 “prediabetes” (defined as dysglycemia to an extent that indicates a high risk of developing
77 diabetes), and type 2 diabetes mellitus.^[1, 2] Moreover, patients with cutaneous LE (CLE) smoke at
78 higher rates than in the general population.^[3-5] Second, numerous studies using arterial
79 ultrasonography, coronary CT angiography, and other methods have shown that LE patients
80 carry an increased burden of atherosclerotic plaques compared with the general population.^[1, 6-9]
81 Third, the increased rate of ASCVD events amongst LE patients persists even after adjustment
82 for age and sex and, more strikingly, even after adjustment for other conventional risk factors for
83 ASCVD events.^[1, 10, 11] We have suggested that autoimmune processes specific to LE may
84 exacerbate specific, known pathogenic steps in atherosclerosis.^[11]

85 Despite their high plaque burden and heightened risk for ASCVD events, however, LE
86 patients remain undertreated for the causative agents of ASCVD, meaning low-density
87 lipoprotein (LDL) and other cholesterol-rich apolipoprotein-B (apoB)-containing lipoproteins,^{[12,}
88 ^{13]} and key exacerbators of ASCVD, such as hypertension, smoking, and hyperglycemia.^[1, 14-17]
89 As part of our efforts to address this problem, we recently proposed a system for assessing CLE
90 and systemic LE (SLE) patients using four defined categories of ASCVD event risk, with

91 corresponding guidance for clinical management of LE patients in each ASCVD event risk
92 category using lifestyle modifications and modern medications.^[1]

93 In the current work, we performed a single-center study of all 370 patients with CLE,
94 without or with concurrent SLE, within our established longitudinal cohort at the University of
95 Pennsylvania Health System (UPHS) for whom we have full access to their medical records.^[18-23]
96 Our goal was to assess the state of current management of ASCVD event risk through
97 conventional therapeutic targets, chiefly hyperlipidemia, hypertension, smoking, prediabetes, and
98 diabetes mellitus, in the light of the new recommendations.^[1] We also studied two earlier and still
99 widely used online tools for estimating the risk of an ASCVD event in the next 10 years (“10-
100 year ASCVD event risk”) for individuals without clinically evident ASCVD (primary
101 prevention) from the general population, i.e., not specifically designed for CLE patients: the
102 American College of Cardiology (ACC) ASCVD Risk Estimator Plus^[24, 25] and the QRisk3
103 calculator.^[26-28]

104 **Methods**

105 *The LE-ASCVD Study Cohort*

106 We previously reported the UPenn Longitudinal Lupus Cohort, which is our established
107 cohort of patients receiving care at UPHS whom we have been recruiting from our specialty
108 Dermatology clinic since 2007 based on a diagnosis of CLE, without or with concurrent SLE.¹¹⁸⁻
109 ^{23]} The UPHS Institutional Review Board approved patient recruitment and then collection and
110 analyses of data, and we obtained written informed consent from each participant. This study
111 followed the principles outlined in the Declaration of Helsinki.

112 For the current study, we required full access to longitudinal and recent medical records.
113 Thus, we included only active UPHS patients and patients whose records from outside hospitals
114 were either linked or faxed into the UPHS electronic medical record (“LE-ASCVD Study
115 Cohort”). Our database consisted of clinical information for these patients, including ASCVD
116 events and conventional parameters relevant to management of future ASCVD event risk, that
117 we entered into the University’s secure RedCap system (Research Electronic Data Capture,
118 Vanderbilt University, Nashville, TN, USA) to ensure compliance with confidentiality
119 requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

120

121 *Collection and interpretation of clinical data*

122 Our approaches for collecting and interpreting these data are described in detail in the
123 Supplementary Methods, in the sections, *Demographic and clinical data collected for the*
124 *RedCap database and Three systems to estimate the risk of a future ASCVD event for individual*
125 *patients within the LE-ASCVD Study Cohort.*

126 Among the conventional parameters relevant to future ASCVD event risk, the
127 lipid/lipoprotein panels in the patients' electronic charts uniformly included plasma
128 concentrations of total cholesterol (TC), LDL cholesterol (LDLc), triglycerides (TG), and high-
129 density lipoprotein cholesterol (HDLc), but not apolipoprotein-B (apoB) nor a one-time assay for
130 lipoprotein(a) [Lp(a)].^[1, 29-31] Non-HDLc, a convenient parameter that captures the cholesterol
131 carried by LDL and all other atherogenic apoB-containing lipoproteins, was calculated as TC
132 minus HDLc.

133 All previously documented or newly incident major adverse atherosclerotic
134 cardiovascular events (MAACE) were noted along with the event date and were defined as
135 atherosclerotic myocardial infarction (MI), atherosclerotic ischemic heart disease other than MI
136 such as angina and coronary revascularization, atherosclerotic (non-embolic) ischemic stroke or
137 transient cerebrovascular ischemic attack, newly diagnosed symptomatic peripheral arterial
138 disease (PVD), or hospitalization for chest pain, shortness of breath, or palpitations with
139 suspicion of ischemic origin. Major adverse cardiovascular events (MACE) that were clearly not
140 atherosclerotic were excluded, such as coronary vasospasm without documentation of nearby
141 plaque, venous thrombosis or pulmonary embolism, embolic stroke unrelated to atherosclerosis,
142 and heart failure from non-ischemic causes (chronic hypertension, diabetes mellitus, non-
143 ischemic valvular disorders, post-myocarditis, and congenital or genetic defects).

144

145 *Statistical analyses*

146 Categorical parameters are given as n (%). Continuous variables are given as mean±SD,
147 if normally distributed, or as median (interquartile range, IQR), if non-normally distributed.

148 To assess the correlation between the numerical estimates of 10-year ASCVD event risk
149 from the QRisk3 versus the ACC Risk Estimator Plus for all patients in the LE-ASCVD Study
150 Cohort for whom we could use both, we calculated a Pearson's correlation coefficient (r) and fit
151 a linear regression. Documented MAACE were tabulated for the period before enrollment into
152 the Cohort and then for the entire period of study after enrollment. Event-free survival rates
153 since enrollment in the LE-ASCVD Study Cohort were computed according to Kaplan & Meier,
154 along with 95% confidence intervals.^[32, 33]

155 **Results**

156 The UPenn Longitudinal Lupus Cohort currently consists of 529 CLE patients.^[21-23] Upon
157 review, we found that 370 of them have electronic medical records that are fully accessible
158 within UPHS and therefore could be included in our LE-ASCVD Study Cohort.

159 Table 1 shows demographics and other characteristics of the LE-ASCVD Study Cohort.
160 Consistent with our previous reports,^[1, 21, 23] the LE-ASCVD Study Cohort was predominantly
161 female (82.4%), with nearly nine out of 10 identifying as White (51.4%) or Black (38.1%),
162 consistent with the UPHS catchment area. Average age was 47.1±14.9 years at enrollment and
163 54.8±15.9 years at the end of the data collection period (Table 1). Average length of time since
164 enrollment into the UPenn Longitudinal Lupus Cohort was 7.7±4.5 years.

165 As of their most recent medical encounter, 22.2% of the patients in our LE-ASCVD
166 Study Cohort had clinically evident ASCVD, meaning a diagnosis of MAACE as defined in the
167 Methods, which classifies these individuals as candidates for secondary prevention (n=82/370;
168 Extreme Risk in Table 1 and in Figure 1A; no patient qualified for the highest-risk category from
169 Keyes et al. of Recent Recurrent ASCVD Events). Just over half of the LE-ASCVD Study
170 Cohort had concurrent SLE (51.4%), with 11.4% having a history of lupus nephritis, and 10.0%
171 having a history of stage 3 or 4 CKD. Median times since diagnosis of CLE or concurrent SLE
172 were over a decade (Supplementary Table S1).

173 Almost three-quarters of the patients in the LE-ASCVD Study Cohort (71.9%, Table 1)
174 had hypertension, defined as a systolic blood pressure ≥130, a diastolic pressure ≥80 mm Hg,
175 and/or on anti-hypertensive medication, following the recently updated joint guidelines from the
176 ACC and the American Heart Association (AHA).^[17, 34] Of the Study Cohort, 29.5% were former
177 smokers, and 17.0% are current smokers (Table 1). Of the subgroup with at least one set of

178 simultaneous height and weight measurements, approximately one-third were underweight or
179 normal weight (n=125/346, 36.2%), one-third overweight (30.3%), and one-third obese (33.5%;
180 Table 1 and Supplementary Table S1). Prediabetes was present in 18.1%, and diabetes in 10.5%,
181 of the LE-ASCVD Study Cohort (Table 1). A diagnosis of depression was common (37.6%;
182 Supplementary Table S1), as previously reported for CLE.^[35]

183 Regarding management, nearly all the patients in the LE-ASCVD Study Cohort had a
184 primary-care physician (PCP) listed in the electronic medical record (90.8%; Table 1). Time
185 elapsed since the last visit with a primary-care physician was 10 months (IQR 4.0-31;
186 Supplementary Table S1). Number of physician providers, excluding trainees, was 5.8±2.8 per
187 patient (mean±SD; Supplementary Table S1). Most patients in the Study Cohort had seen a
188 rheumatologist (203/307, 54.9%), and under half had seen a cardiologist (40.8%), nephrologist
189 (15.4%), or endocrinologist (8.0%; Supplementary Table S1).

190

191 *Assessments and management of lipid/lipoprotein levels as targets to lower ASCVD event risk*

192 The vast majority (n=325/370, 87.8%) of patients in the LE-ASCVD Study Cohort had
193 plasma lipid/lipoprotein levels checked at least once, with a median elapsed time of 35 months
194 (IQR 14-83) since the most recent panel, i.e., almost three years (Supplementary Table S1). We
195 found that PCPs checked just over 60% of the most recent lipid/lipoprotein values, and non-
196 PCPs checked the rest. Of the non-PCPs, rheumatologists checked lipid/lipoprotein values in
197 more patients than did other subspecialists (Supplementary Table S1).

198 Based on data from the electronic charts, including absence (primary prevention) or
199 presence (secondary prevention) of clinically evident ASCVD, as well as major conventional
200 risk factors for ASCVD events, we classified patients from the LE-ASCVD Cohort into the four

201 defined categories of ASCVD event risk from our recently proposed guidelines for LE patients –
202 namely, High Risk, Very High Risk, Extreme Risk, and Recent Recurrent ASCVD Events.^[1]
203 Next, we compared current clinical care with the new therapeutic goals for each of these
204 categories of ASCVD event risk for LE patients.^[1]

205 We found that almost one-quarter of LE patients classified at High Risk for an ASCVD
206 event had plasma LDLc concentrations that were above the newly recommended ranges
207 (n=11/52, 21.2%; red in the leftmost column of Figure 1A). More strikingly, over three-quarters
208 of LE patients classified at either Very High Risk (179/236, 75.8%) or Extreme Risk (62/82,
209 75.6%) for an ASCVD event also had plasma LDLc concentrations above the newly
210 recommended ranges (red in the middle two columns of Figure 1A). For the 252 LE patients
211 whose most recent LDLc value was above-goal, the time elapsed since that above-goal LDLc
212 was 47 months (IQR 24-97), i.e., almost four years (Supplementary Table S1). Data for non-
213 HDLc levels were similar: 13.5% (7/52), 66.5% (157/236), and 72.0% (59/82) of our LE patients
214 in these three categories of ASCVD event risk had values above the newly recommended ranges
215 (Supplementary Figure S1A).

216 Regarding lipid/lipoprotein management in primary prevention, 90.9% (n=10/11) of High
217 Risk patients with out-of-range LDLc levels were not on any LDL-lowering medications
218 recorded in their charts, and 70.4% (n=126/179) of Very High Risk patients with out-of-range
219 LDLc levels were not on LDL-lowering medications (Figure 1B). Again, data for non-HDLc
220 levels were similar: 85.7% (6/7), and 72.6% (114/157) of LE patients in these two categories of
221 ASCVD event risk with out-of-range non-HDLc levels were not on any LDL-lowering
222 medications (Supplementary Figure S1B). Thus, over two-thirds of LE patients classified at High

223 or Very High ASCVD event risk with out-of-range LDLc or non-HDLc values according to the
224 newly published guidelines were on no LDL-lowering medications.

225 Of the 82 LE patients classified at Extreme ASCVD event risk (secondary prevention),
226 only about one in ten achieved plasma concentrations of LDLc (8/82, 9.8%) or non-HDLc
227 (11/82, 13.4%) within the new goals. Nearly half were under-treated by the new guidelines,
228 meaning on LDL-lowering medications but still with out-of-range values for LDLc (37/82,
229 45.1%) or non-HDLc (34/82, 41.5%). About 30% were untreated, meaning out-of-range values
230 for LDLc (25/82, 30.5%) or non-HDLc (also 25/82, 30.5%) yet on no LDL-lowering
231 medications. The remainder of the LE patients classified at Extreme ASCVD event risk had no
232 LDLc (12/82, 14.6%) or HDLc (also 12/82, 14.6%) values available from their charts despite
233 documentation of clinically evident ASCVD, the key requirement for this risk category^[1] (Figure
234 1B, Supplementary Figure S1B).

235 We used the ACC ASCVD Risk Estimator Plus^[24, 25] to estimate the risk of an ASCVD
236 event in the next 10 years (“10-year ASCVD event risk”) for all patients in the LE-ASCVD
237 Study Cohort meeting the criteria of no clinically evident ASCVD (primary prevention,
238 n=288/370, 77.8% of the Study Cohort; Figure 1A, Table 1), with sufficient available clinical
239 data to allow use of this online risk estimator (n=254), and ages 40-79 years, a stated requirement
240 for this online calculator to estimate 10-year ASCVD event risks (n=194). By performing age-
241 scaling as described in the Supplementary Methods, we included an additional 47 patients below
242 the age of 40 years (12.7% of the LE-ASCVD Study Cohort) and 13 patients above 79 years
243 (3.5% of the Study Cohort) without clinically evident ASCVD and with sufficient data for this
244 online ASCVD event risk estimator, to analyze the entire subset of 254 patients just mentioned,

245 i.e., nearly 90% of the LE-ASCVD Study Cohort who had no clinically evident ASCVD
246 (254/288, 88.2%).

247 Figure 1C displays data for these 254 patients stratified by estimates of their 10-year
248 ASCVD event risk from the ACC ASCVD Risk Estimator Plus, following the cutoffs of Arnett
249 et al. in the ACC/AHA guidelines for primary prevention of cardiovascular disease in the general
250 population – namely, 0.0-4.9% 10-year ASCVD event risk (low), 5.0-7.4% (borderline), 7.5-
251 19.9% (intermediate), and $\geq 20\%$ (high).^[25] Of the patients with an estimated 10-year ASCVD
252 event risk of 7.5% to 19.9% from the ACC ASCVD Risk Estimator Plus, over half were not on
253 any LDL-lowering medication (n=43 out of 73, 58.9%; Figure 1C). Of patients with an estimated
254 10-year ASCVD event risk $\geq 20\%$, 42.9% (n=12/28) were not on an LDL-lowering medication
255 recorded in the chart. Supplementary Figure S1C shows nearly identical results from the original
256 subset of 194 LE patients with no clinically evident ASCVD, sufficient data for this online risk
257 estimator, and aged 40-79 years with no age-scaling.

258 Of the LE patients who already have clinically evident ASCVD and are therefore
259 candidates for secondary prevention of ASCVD events, 41.5% (n=34/82) were not on any LDL-
260 lowering medication; this figure comprises Extreme Risk patients on no LDL-lowering
261 medication who have either (i) no LDLc value available (7 out of 12 from Figure 1A), (ii) the
262 most recent LDLc value within goal (2 out of 8 from Figure 1A), or (iii) the most recent LDLc
263 value above goal (25 from Figure 1B).

264 Supplementary Figure S1D shows data for patients in the LE-ASCVD Study Cohort
265 stratified by their most recent plasma LDLc concentrations, and then within each LDLc
266 concentration range, we indicate treatment, or not, with an LDL-lowering medication. In each
267 LDLc concentration range, except for the lowest (<70 mg/dl) and the highest (≥ 190 mg/dl), over

268 60% of our LE patients were on no LDL-lowering medications. There was no LDLc value
269 available in the chart for 45 patients (12.2% of the entire LE-ASCVD Study Cohort), nearly all
270 of whom were on no LDL-lowering medications (n=39/45, 86.7%). Supplementary Figure S1E
271 shows data from stratifying LE patients by their most recent plasma non-HDLc concentrations.
272 Similar to our findings with LDLc, in each concentration range of non-HDLc, except for the
273 lowest (<80 mg/dl) and the highest (≥ 220 mg/dl), over 60% of LE patients were on no LDL-
274 lowering medications (Supplementary Figure S1E).

275

276 *Assessments and management of hypertension*

277 As noted above, almost three-quarters of the LE-ASCVD Study Cohort had hypertension
278 (266/370, 71.9%; Table 1). Of these 266 hypertensive lupus patients, approximately one-fourth
279 were well-managed, meaning normotensive on anti-hypertensive medications (68/266, 25.6%;
280 green in the leftmost column of Figure 2A); almost one half were under-treated, meaning on anti-
281 hypertensive medications but still hypertensive (122/266, 45.9%; green in the middle column of
282 Figure 2A); and almost one third were untreated, meaning hypertensive yet on no anti-
283 hypertensive medication (76/266, 28.6%; red in the middle column of Figure 2A). These data
284 indicate that hypertension is a common but undermanaged problem in lupus patients, consistent
285 with recently published literature using these blood pressure cut-offs.^[17]

286

287 *Smoking status and management*

288 Figure 2B indicates the prevalence and management of tobacco smoking in the LE-
289 ASCVD Study Cohort. Of the former smokers in our cohort, the overwhelming majority quit
290 smoking without any documentation in the chart of smoking cessation counseling or referral to a

291 specialized smoking cessation clinic (n=92/109, 84.4%). Similarly, the overwhelming majority
292 of current smokers have no documentation in their charts of smoking cessation counseling or
293 clinic referral (n=51/63, 81.0%).

294

295 *Assessments and management of glycated hemoglobin (HbA_{1c}) and plasma triglyceride levels*

296 The majority (n=208/370, 56.2%) of patients in the LE-ASCVD Study Cohort had their
297 HbA_{1c} levels checked at least once, with a median time elapsed time of 36 months (IQR 11-68)
298 since the last assay, i.e., three years (Supplementary Table S1). As with lipid/lipoprotein values,
299 PCPs checked just over 60% of the most recent HbA_{1c} levels, and non-PCPs checked the rest. Of
300 the non-PCPs, rheumatologists checked HbA_{1c} levels in more patients than did other
301 subspecialists (Supplementary Table S1).

302 Figure 2C shows assessment, or not, of HbA_{1c} values in the LE-ASCVD Study Cohort
303 after stratification by obesity and/or current or previous glucocorticoid use, two common factors
304 in lupus patients that impair glycemic control. Of note, 51.0% (51 out of 100) of non-obese LE
305 patients on glucocorticoids, 30.6% (22/72) of obese LE patients not on glucocorticoids, and
306 38.6% (17/44) of obese LE patients on glucocorticoids had no HbA_{1c} value in their electronic
307 charts. In those three groups, 17.0% (n=17/100), 47.2% (n=34/72), and 31.8% (n=14/44) of the
308 patients had documented prediabetes or diabetes (blue and yellow in Figure 2C), suggesting that
309 obesity is a bigger driver of dysglycemia in the LE-ASCVD Study Cohort than are GCs. For
310 comparison, the figure for non-obese LE patients not on glucocorticoids is 23.4% (n=36/154;
311 leftmost column in Figure 2C). For patients whose most recent HbA_{1c} value was indicative of
312 prediabetes or diabetes, meaning $\geq 5.7\%$,^[36] the time elapsed since that abnormal value was 48
313 months (IQR 24-80), i.e., four years (Supplementary Table S1).

314 For LE patients with a diagnosis of prediabetes, almost half (33/67, 49.3%) did not meet
315 either of the two key criteria for well-managed prediabetes – namely, documentation of lifestyle
316 modification counseling or an active prescription for metformin prescription in their charts^[36-40]
317 (Figure 2D). For LE patients with diabetes, however, over three-quarters were well-managed,
318 generally defined as the most recent HbA_{1c} ≤7%^[36-40] (n=30/39, 76.9%), and only 10.3% (4/39)
319 had a most recent HbA_{1c} >7% (Figure 2D).

320 Regarding triglyceride management, only 10.0% (10/100) of non-obese LE patients on
321 glucocorticoids, 5.6% (4/72) of obese LE patients not on glucocorticoids, and 9.1% (4/44) of
322 obese LE patients on glucocorticoids had no plasma triglyceride value in their electronic charts
323 (Figure 2E). Of all patients in the LE-ASCVD Study Cohort with available triglyceride values
324 (n=331 out of 370, 89.5%), only 0.6% (2/331) had very high levels (≥500 mg/dl) and only 6.0%
325 (20/331) had high levels (200-499 mg/dl; Figure 2E). These data indicate that
326 hypertriglyceridemia was not a common problem in our LE-ASCVD Study Cohort even amongst
327 patients with obesity and/or glucocorticoid therapy.

328

329 *Comparisons of three different systems for estimating the risk of future ASCVD events in LE*
330 *patients*

331 We examined three systems for estimating the risk of future ASCVD events in LE
332 patients – namely, the newly proposed risk categories of Keyes et al, which include both primary
333 and secondary prevention,^[1] and the two widely used online risk calculators, cited above, that
334 estimate 10-year ASCVD event risk and are limited to primary prevention. To compare these
335 systems in our LE-ASCVD Study Cohort, we focused on the subset of patients for whom both
336 the QRisk3 and the ACC ASCVD Risk Estimator Plus could be used, meaning sufficient data in

337 the electronic chart and no clinically evident ASCVD (n=254 out of 370 when including age-
338 scaling, i.e., the same number classified by the ACC ASCVD Risk Estimator Plus in Figure 1C).
339 We separated these 254 patients into “High Risk” (n=41 out of 254; blue dots in Figure 3A and
340 Supplementary Figure S2A) and “Very High Risk” (n=213/254; yellow dots in Figure 3A and
341 Supplementary Figure S2B) following the categories of Keyes et al.^[1] None of these 254 LE
342 patients met criteria for the categories of “Extreme Risk” or “Recent Recurrent ASCVD Events”
343 from Keyes et al., because both of those categories require clinically evident ASCVD, hence
344 secondary prevention and ineligible for the QRisk3 or ACC ASCVD risk estimators.

345 Figure 3A shows estimates of each of these patient’s 10-year ASCVD event risk from the
346 QRisk3 and from the ACC calculator. Supplementary Figure S2A shows both estimates of 10-
347 year ASCVD event risk for only the LE patients who were stratified into the “High Risk”
348 category of Keyes et al., with the axes expanded for ease of viewing the data. Supplementary
349 Figure S2B shows both 10-year ASCVD event risk estimates for only the LE patients stratified
350 into the “Very High Risk” category of Keyes et al. Supplementary Figure S2B allows an
351 unobstructed view of the data for these Very High Risk patients, indicating that many of them
352 had remarkably low estimates of 10-year ASCVD event risk from one or both of the online
353 calculators, a point we return to in Figure 3B.

354 To directly compare the numerical estimates of 10-year ASCVD event risk from the
355 QRisk3 and the ACC ASCVD Risk Estimator Plus in our LE-ASCVD Study Cohort, we
356 performed Pearson’s correlation with age-scaling (Figure 3A, n=254 patients) and without age-
357 scaling (Supplementary Figure S2C, n=194 patients, i.e., the same number classified by the ACC
358 ASCVD Risk Estimator Plus in Supplementary Figure S1C). Correlations were highly
359 statistically significant, with p-values of 1.78×10^{-41} and 1.40×10^{-27} , respectively. Nevertheless,

360 the r^2 values were surprisingly low, at 0.52 and 0.46, respectively. In other words, in our Study
361 Cohort, only about half of the variation in one widely used online 10-year ASCVD risk estimate
362 can be statistically attributed to variation in the other. Moreover, the y-intercepts were 6.9% and
363 7.7%, which are substantial compared with the cutoffs in the ACC/AHA guidelines for primary
364 prevention of cardiovascular disease in the general population^[25] and indicate generally higher
365 10-year ASCVD risk estimates from the QRisk3 than from the ACC ASCVD Risk Estimator
366 Plus, particularly at the latter's lower end. Visual inspection of Figure 3A and Supplementary
367 Figures S2A-C demonstrates this point as well.

368 Figure 3B indicates clinically meaningful agreement (green) and discordance (red, white)
369 amongst the three systems for estimating the risk of a future ASCVD event for individual
370 patients in the LE-ASCVD Study Cohort. We compared the two online calculators with the
371 newly proposed categories of ASCVD event risk for LE patients from Keyes et al. by using the
372 key cutoff of 7.5% estimated 10-year ASCVD event risk from the ACC/AHA guidelines for
373 primary prevention of cardiovascular disease in the general population, because estimates $\geq 7.5\%$
374 come with substantially more aggressive recommendations for management compared with the
375 recommendations for patients with estimates $< 7.5\%$.^[25] In Figure 3B, green indicates clinically
376 meaningful agreement, defined here as classification of an LE patient into the "High Risk" or
377 "Very High Risk" categories of Keyes et al., with estimates of 10-year ASCVD event risk $\geq 7.5\%$
378 from both of the online calculators. Red indicates clinically significant discordance between the
379 two online calculators, meaning one estimate of 10-year ASCVD event risk $< 7.5\%$ but the other
380 $\geq 7.5\%$ for the same LE patient. White indicates discordance between Keyes et al. versus both of
381 the online risk estimators, i.e., these patients are at High or Very High Risk according to Keyes
382 et al., yet both online calculators gave estimates of 10-year ASCVD event risk $< 7.5\%$. By these

383 definitions of clinically meaningful agreement and discordance, the three systems for estimating
384 the risk of a future ASCVD event were in agreement for only 100 of the 254 LE patients
385 (39.4%), i.e., discordance for almost two-thirds of the LE patients (154/254, 60.6%) that could
386 affect their clinical management. Supplementary Figure S2D shows similar findings for the 194
387 LE patients without age-scaling.

388

389 *Clinically documented ASCVD Events and actual 10-year ASCVD event rate in the LE-ASCVD* 390 *Study Cohort*

391 Because of discordances amongst the three systems for estimating ASCVD event *risk*
392 (Figure 3, Supplemental Figure S2), we sought to determine the actual 10-year ASCVD event
393 *rate* in our LE-ASCVD Study Cohort. Figure 4 shows the Kaplan-Meier curve of event-free
394 survival, with 95% confidence intervals, since enrollment. For completeness, Supplementary
395 Figure S3 shows the cumulative incidence of all documented MAACE in our LE-ASCVD Study
396 Cohort, including the period before enrollment (indicated at time 0) and then all first MAACE
397 after enrollment (time >0). Table 2 gives a breakdown of the types of MAACE.

398 The rate of ASCVD events for patients in the first 10 years after enrollment into our LE-
399 ASCVD Study Cohort was calculated as one minus the event-free survival at the 10-year time
400 point of the Kaplan-Meier survival curve (Figure 4). Thus, the 10-year ASCVD event rate was
401 22.3% (95% CI 16.9%, 27.4%), which is above Arnett et al.'s highest cut-off of 20%,^[25]
402 indicating a high-risk population.

403 This 10-year ASCVD event rate in our LE-ASCVD Study Cohort is even more striking,
404 given the preponderance of women and the patients' relative youth at enrollment (Table 1). For
405 comparison, the ACC ASCVD Risk Estimator Plus gives an estimate of 10-year ASCVD event

406 risk $\geq 20\%$ for a 47-year-old woman if she has a combination of diabetes, current smoking,
407 treated hypertension, an HDLc of 40 mg/dl, and a non-HDLc ≥ 250 mg/dl if Caucasian and ≥ 160
408 mg/dl if African-American.

409 **Discussion**

410 Our results indicate that CLE patients are under-treated compared with the new
411 guidelines for conventional therapeutic targets to prevent ASCVD events^[1] and, accordingly,
412 these patients experience a substantial burden of major adverse ASCVD events despite our
413 youngish, predominantly female LE-ASCVD Study Cohort. Moreover, current methods give
414 discordant estimates of the risk for future ASCVD events, possibly because the online risk
415 calculators were not designed specifically for CLE patients. Thus, for patients with cutaneous
416 LE, it is unclear how to accurately assess their future ASCVD event risk – except that it is high –
417 and this uncertainty may complicate clinical management. Management of ASCVD event risk
418 has become a major issue in LE because of therapeutic success: lupus patients are now much less
419 likely to die prematurely from lupus directly or from infections, and so they are living long
420 enough to develop clinically significant atherosclerotic cardiovascular disease.^[1, 6]

421 Specific areas of current concern include under-management of plasma LDLc, non-
422 HDLc, and presumably apoB levels to the new guidelines;^[1] under- or non-administration of
423 LDL-lowering therapies in primary and even secondary prevention; under-management of
424 hypertension to recently revised blood-pressure goals;^[17, 34] under-use of resources for smoking
425 cessation; infrequent monitoring of above-goal LDLc and HbA_{1c} levels; under-management of
426 prediabetes; and, as noted above, clinically meaningful discordances in estimates of the risk for
427 future ASCVD events and a strikingly high 10-year ASCVD event rate. Areas of current success
428 include high levels of linkage with a PCP; evidence of widespread awareness amongst PCPs and
429 sub-specialists of conventional therapeutic targets for management of ASCVD event risk;
430 generally well-managed diabetes mellitus; and a low prevalence of hypertriglyceridemia in the
431 LE-ASCVD Study Cohort even in patients with obesity and/or GC use.

432 Our findings add to a growing literature emphasizing the gaps between typical or usual
433 real-world care versus ideal guideline-based care in the management of ASCVD event risk in
434 lupus patients and in non-autoimmune populations, even ones at high risk. Several studies have
435 looked at rates of cardiovascular events in CLE cohorts.^[1, 11] To our knowledge, however, ours is
436 the first study to focus on the management of ASCVD event risk in CLE, although there is a
437 prior literature in SLE.^[11] In one published study, a large proportion of a cohort of 110 patients
438 with SLE had indications for statins for primary or secondary prevention, but only about half of
439 them were treated to guidelines.^[16] In a recently reported cohort of 1532 SLE patients,^[17] 639 had
440 hypertension defined by the new cutoffs of $\geq 130/\geq 80$ mm Hg or on anti-hypertensive
441 medications, but approximately three-quarters of these hypertensive SLE patients (471/639,
442 73.7%) were under- or un-treated, nearly identical to our figure of 74.4% (198/266, Figure 2A).
443 Moreover, lupus patients with blood pressures in the newly defined range for stage 1
444 hypertension, meaning 130–139/80–89 mm Hg,^[34] had more than twice the rate of atherosclerotic
445 cardiovascular events than did normotensive lupus patients during a decade or so of follow-up.^{[17,}
446 ^{41]} In other SLE cohorts as well, persistent hypertension has been associated with a much higher
447 incidence of ASCVD events, compared with ASCVD event rates in normotensive SLE
448 patients.^[42]

449 In non-autoimmune populations, treatment of therapeutic targets to manage ASCVD
450 event risk, particularly hypercholesterolemia^[43-47] and hypertension,^[48, 49] remains sub-optimal in
451 the USA and worldwide. Particularly striking are under-utilization of evidence-based LDL- and
452 blood pressure-lowering medications in patients with diabetes mellitus,^[50, 51] even when those
453 patients are at extreme ASCVD event risk owing to the additional presence of clinically evident
454 atherosclerosis (secondary prevention) on top of their type 2 diabetes.^[46]

455 Reasons for this widespread pattern of undertreatment might stem from prioritization of
456 immediate clinical problems over long-term care, difficulties for patients and providers in
457 sustaining long-term treatment for subclinical conditions, time needed to disseminate and
458 implement recent guidelines, access to care, the difficulties of polypharmacy, evidence-based
459 and non-evidence-based concerns from patients and providers over potential side-effects,^[47, 52]
460 and lifestyle and medication adherence. Further research is needed so that rational strategies can
461 be developed to address under-management of ASCVD event risk. Amongst conventional
462 therapeutic targets in the management of ASCVD event risk, levels of LDLc, non-HDLc, and
463 apoB can be managed without great concern of a lower limit using current agents,^[53, 54] in
464 contrast to blood pressure or plasma glucose levels. Conventional interventions to assist
465 smoking cessation and to manage prediabetes also come with few risks.

466 Notably, our results emphasize the need to clarify how to appropriately assess the risk of
467 future ASCVD events in CLE patients. We demonstrated discordance amongst the three systems
468 that we used: the new risk classifications from Keyes et al. specifically for lupus patients,^[1] the
469 ACC ASCVD Risk Estimator Plus,^[24, 25] and the QRisk3 calculator.^[26-28] A similar discordance
470 between the Framingham Risk Score and QRisk3 was recently reported for SLE patients in one
471 study^[55] but less so in another study with a far smaller cohort.^[16] As a statistical matter,
472 multiplying the 10-year estimate from the ACC Risk Estimator Plus by 1.5, as has been
473 proposed,^[1, 56] would not improve the r^2 value of the correlation with QRisk3. Recent reports
474 suggest that QRisk3 may be a better predictor for lupus patients than other estimators of future
475 ASCVD event risk.^[57, 58] Additional clinical parameters that may enhance assessment of ASCVD
476 event risk in lupus patients may include plasma apoB measurements,^[1, 59] one-time assessments
477 of plasma lipoprotein(a) levels, which are still largely genetically determined^[1], and arterial

478 imaging to detect subclinical plaque by iliofemoral or carotid ultrasonography or magnetic
479 resonance imaging; coronary, iliofemoral, or carotid coronary CT angiography; and in older
480 patients coronary artery calcium scores.^[1]

481

482 *Study Limitations and Strengths*

483 Study limitations include the retrospective design, from a single medical center. In our
484 database, like many others, there are possible inaccuracies in smoking status because assays of
485 cotinine, a recognized marker of nicotine use, are not part of routine care. Lifestyle modifications
486 or medications discussed at a clinic visit but not entered into the charts could indicate a different
487 level of management. In addition, the standard of care for diabetes testing includes assays
488 besides HbA_{1c}, such as fasting glucose levels, oral glucose tolerance tests (OGTT), and random
489 plasma glucose levels, which may also be used to diagnose and assess prediabetes and
490 diabetes.^[36] As noted in Figure 2C, many patients in our LE-ASCVD Study Cohort had no
491 available HbA_{1c} values, which affects our statistics on prevalence of prediabetes and diabetes and
492 their management

493 Study strengths include a well-characterized longitudinal Cohort followed for over 14
494 years, with key parameters available in the electronic charts. The study assessed all available
495 conventional therapeutic targets in managing ASCVD event risk, which has not been previously
496 done in a comprehensive manner in CLE patients. Moreover, our results identified specific, key
497 issues in clinical management and decision-making.

498 **Conclusions**

499 Cutaneous LE patients are under-treated compared with the new guidelines and, accordingly,
500 they experience a substantial burden of ASCVD events. Moreover, it is unclear how to
501 accurately assess future ASCVD event risk in these patients – except that it is high – and this
502 uncertainty may complicate clinical management. Based on our findings, efforts are now
503 underway to improve ASCVD event risk estimation and guideline implementation in lupus
504 patients.

505 **List of Abbreviations:**

- 506 • ACC, American College of Cardiology
- 507 • AHA, American Heart Association
- 508 • apoB, apolipoprotein-B
- 509 • ASCVD, atherosclerotic cardiovascular disease
- 510 • CLE, cutaneous lupus erythematosus
- 511 • HbA_{1c}, glycated hemoglobin
- 512 • HDLc, high-density lipoprotein cholesterol
- 513 • Lp(a), lipoprotein(a)
- 514 • LDLc, low-density lipoprotein cholesterol
- 515 • LE, lupus erythematosus
- 516 • MAACE, major adverse atherosclerotic cardiovascular event
- 517 • MACE, major adverse cardiovascular event
- 518 • MI, myocardial infarction,
- 519 • OGTT, oral glucose tolerance test
- 520 • PAD, peripheral arterial disease
- 521 • PCP, primary care physician
- 522 • SLE, systemic lupus erythematosus
- 523 • TC, total cholesterol
- 524 • TG, triglycerides
- 525 • UPHS, University of Pennsylvania Health System

526 *Contributions: MZ, VPW, and KJW, were involved in the conceptualizing the project, writing the*
527 *manuscript, and editing the manuscript. MZ was responsible for data collection, and MZ and*
528 *KJW were responsible for data verification. MZ, RF, and KJW were responsible for data*
529 *analysis.*

530 *Funding: Support by the Lupus Foundation of America was given for this study as part of the*
531 *2021 Gina M. Finzi Student Fellowship (to MZ). The work was also supported by the National*
532 *Institutes of Health-USA (NIH-USA) grants K24-AR02207 and R01AR071653 (to VPW), the*
533 *United States Department of Veterans Affairs (Veterans Health Administration, Office of*
534 *Research and Development and Biomedical Laboratory Research and Development, to VPW),*
535 *and the Ruth and Yonatan Ben-Avraham Fund (to KJW).*

536 *Competing interests: All authors declare no support from any commercial organization for the*
537 *submitted work; no financial relationships with any organizations that might have an interest in*
538 *the submitted work in the previous three years; no other relationships or activities that could*
539 *appear to have influenced the submitted work. KJW discloses an ownership interest in Hygieia,*
540 *Inc., a company that provides insulin management services.*

541 *Data sharing: De-identified patient-level data, the full dataset, and statistical code are available*
542 *from the first author (MZ, megan.zhao@pennmedicine.upenn.edu). Participant consent for data*
543 *sharing was not obtained but the presented data are anonymized and risk of identification is low.*

544 *Ethics: This study was approved by the University of Pennsylvania Institutional Review Board;*
545 *IRB PROTOCOL#: 849182*

546 *Transparency Declaration: This manuscript is an honest, accurate, and transparent account of*
547 *the study being reported. There are no important aspects of the study have been omitted and*
548 *discrepancies have been explained. There are no competing interests.*

549

550 **References**

- 551 1. Keyes, E., et al., *Assessment and management of the heightened risk for atherosclerotic*
552 *cardiovascular events in patients with lupus erythematosus or dermatomyositis*. Int J
553 Womens Dermatol, 2021. **7**(5Part A): p. 560-575.
- 554 2. Akarsu, S., et al., *High Prevalence of Metabolic Syndrome in Patients with Discoid*
555 *Lupus Erythematosus: A Cross-Sectional, Case-Control Study*. J Immunol Res, 2017.
556 **2017**: p. 3972706.
- 557 3. Miot, H.A., L.D. Bartoli Miot, and G.R. Haddad, *Association between discoid lupus*
558 *erythematosus and cigarette smoking*. Dermatology, 2005. **211**(2): p. 118-22.
- 559 4. Bockle, B.C. and N.T. Sepp, *Smoking is highly associated with discoid lupus*
560 *erythematosus and lupus erythematosus tumidus: analysis of 405 patients*. Lupus, 2015.
561 **24**(7): p. 669-74.
- 562 5. Guo, L.N. and V.E. Nambudiri, *Cutaneous lupus erythematosus and cardiovascular*
563 *disease: current knowledge and insights into pathogenesis*. Clin Rheumatol, 2021. **40**(2):
564 p. 491-499.
- 565 6. Urowitz, M.B., et al., *The bimodal mortality pattern of systemic lupus erythematosus*. Am
566 J Med, 1976. **60**(2): p. 221-5.
- 567 7. Roman, M.J., et al., *Prevalence and correlates of accelerated atherosclerosis in systemic*
568 *lupus erythematosus*. N Engl J Med, 2003. **349**(25): p. 2399-406.
- 569 8. Asanuma, Y., et al., *Premature coronary-artery atherosclerosis in systemic lupus*
570 *erythematosus*. N Engl J Med, 2003. **349**(25): p. 2407-15.
- 571 9. Carlucci, P.M., et al., *Neutrophil subsets and their gene signature associate with vascular*
572 *inflammation and coronary atherosclerosis in lupus*. JCI Insight, 2018. **3**(8).
- 573 10. Salmon, J.E. and M.J. Roman, *Subclinical atherosclerosis in rheumatoid arthritis and*
574 *systemic lupus erythematosus*. Am J Med, 2008. **121**(10 Suppl 1): p. S3-8.
- 575 11. Shams-Eldin, A.N., et al., *Long-term risk of adverse cardiovascular outcomes associated*
576 *with cutaneous lupus erythematosus: a nationwide cohort study*. Clin Rheumatol, 2022.
577 **41**(11): p. 3525-3536.
- 578 12. Williams, K.J. and I. Tabas, *The response-to-retention hypothesis of early atherogenesis*.
579 Arterioscler Thromb Vasc Biol, 1995. **15**(5): p. 551-61.
- 580 13. Borén, J. and K.J. Williams, *The central role of arterial retention of cholesterol-rich*
581 *apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a*
582 *triumph of simplicity*. Curr Opin Lipidol, 2016. **27**(5): p. 473-83.
- 583 14. Elliott, J.R., S. Manzi, and D. Edmundowicz, *The role of preventive cardiology in*
584 *systemic lupus erythematosus*. Curr Rheumatol Rep, 2007. **9**(2): p. 125-30.
- 585 15. Munguia-Realpozo, P., et al., *Systemic lupus erythematosus and hypertension*.
586 Autoimmun Rev, 2019. **18**(10): p. 102371.
- 587 16. Masson, W., et al., *Cardiovascular risk stratification and appropriate use of statins in*
588 *patients with systemic lupus erythematosus according to different strategies*. Clin
589 Rheumatol, 2020. **39**(2): p. 455-462.
- 590 17. Tselios, K., et al., *Impact of the new American College of Cardiology/American Heart*
591 *Association definition of hypertension on atherosclerotic vascular events in systemic*
592 *lupus erythematosus*. Ann Rheum Dis, 2020. **79**(5): p. 612-617.
- 593 18. Moghadam-Kia, S., et al., *Cross-sectional analysis of a collaborative Web-based*
594 *database for lupus erythematosus-associated skin lesions: prospective enrollment of 114*
595 *patients*. Arch Dermatol, 2009. **145**(3): p. 255-60.

- 596 19. Chang, A.Y., et al., *Response to antimalarial agents in cutaneous lupus erythematosus: a*
597 *prospective analysis*. Arch Dermatol, 2011. **147**(11): p. 1261-7.
- 598 20. Piette, E.W., et al., *Impact of smoking in cutaneous lupus erythematosus*. Arch Dermatol,
599 2012. **148**(3): p. 317-22.
- 600 21. Wieczorek, I.T., et al., *Systemic symptoms in the progression of cutaneous to systemic*
601 *lupus erythematosus*. JAMA Dermatol, 2014. **150**(3): p. 291-6.
- 602 22. Keyes, E., et al., *Comparative responsiveness of cutaneous lupus erythematosus patients*
603 *to methotrexate and mycophenolate mofetil: A cohort study*. J Am Acad Dermatol, 2021.
604 **98**(2): p. 447-448.
- 605 23. Zeidi, M., et al., *Increased CD69+CCR7+ circulating activated T cells and STAT3*
606 *expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials*.
607 Lupus, 2022. **31**(4): p. 472-481.
- 608 24. American College of Cardiology. [https://tools.acc.org/ASCVD-Risk-Estimator-](https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#/calculate/estimate/)
609 [Plus/#/calculate/estimate/](https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#/calculate/estimate/)
- 610 25. Arnett, D.K., et al., *2019 ACC/AHA Guideline on the Primary Prevention of*
611 *Cardiovascular Disease: A Report of the American College of Cardiology/American*
612 *Heart Association Task Force on Clinical Practice Guidelines*. Circulation, 2019.
613 **140**(11): p. e596-e646.
- 614 26. Hippisley-Cox, J., C. Coupland, and P. Brindle, *Development and validation of QRISK3*
615 *risk prediction algorithms to estimate future risk of cardiovascular disease: prospective*
616 *cohort study*. BMJ, 2017. **357**: p. j2099.
- 617 27. Edwards, N., et al., *QRISK3 improves detection of cardiovascular disease risk in patients*
618 *with systemic lupus erythematosus*. Lupus Sci Med, 2018. **5**(1): p. e000272.
- 619 28. QRISK3. <https://qrisk.org/three/>
- 620 29. Sniderman, A.D., *How, when, and why to use apolipoprotein B in clinical practice*. Am J
621 Cardiol, 2002. **90**(8A): p. 48i-54i.
- 622 30. Wu, M.F., et al., *Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current*
623 *Understanding and Future Perspectives*. Cardiovasc Drugs Ther, 2019. **33**(6): p. 739-
624 748.
- 625 31. Page, M.M. and G.F. Watts, *Contemporary perspectives on the genetics and clinical use*
626 *of lipoprotein(a) in preventive cardiology*. Curr Opin Cardiol, 2021. **36**(3): p. 272-280.
- 627 32. Kaplan, E.L., and Paul Meier, *Nonparametric estimation from incomplete observations*.
628 Journal of the American statistical association, 1958. **53.282**: p. 457-481.
- 629 33. Rich, J.T., et al., *A practical guide to understanding Kaplan-Meier curves*. Otolaryngol
630 Head Neck Surg, 2010. **143**(3): p. 331-6.
- 631 34. Whelton, P.K., et al., 2017
632 *ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the*
633 *Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A*
634 *Report of the American College of Cardiology/American Heart Association Task Force*
635 *on Clinical Practice Guidelines*. Hypertension, 2018. **71**(6): p. e13-e115.
- 636 35. Hesselvig, J.H., et al., *Increased risk of depression in patients with cutaneous lupus*
637 *erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study*. Br J
638 Dermatol, 2018. **179**(5): p. 1095-1101.
- 639 36. American Diabetes Association, 2. *Classification and Diagnosis of Diabetes: Standards*
640 *of Medical Care in Diabetes-2021*. Diabetes Care, 2021. **44**(Suppl 1): S15-S33.

- 641 37. Knowler, W.C., et al., *Reduction in the incidence of type 2 diabetes with lifestyle*
642 *intervention or metformin*. N Engl J Med, 2002. **346**(6): p. 393-403.
- 643 38. Nathan, D.M. and D.E.R. Group, *The diabetes control and complications*
644 *trial/epidemiology of diabetes interventions and complications study at 30 years:*
645 *overview*. Diabetes Care, 2014. **37**(1): p. 9-16.
- 646 39. Diabetes Prevention Program Research, G., *Long-term Effects of Metformin on Diabetes*
647 *Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention*
648 *Program and Diabetes Prevention Program Outcomes Study*. Diabetes Care, 2019. **42**(4):
649 p. 601-608.
- 650 40. Goldberg, R.B., et al., *Effects of Long-term Metformin and Lifestyle Interventions on*
651 *Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study*.
652 *Circulation*, 2022. **145**(22): p. 1632-1641.
- 653 41. Ming Wang, T.K., et al., *Cardiovascular Manifestations, Imaging, and Outcomes in*
654 *Systemic Lupus Erythematosus: An Eight-Year Single Center Experience in the United*
655 *States*. *Angiology*, 2022. **73**(9): p. 877-886.
- 656 42. Kiani, A.N., et al., *Predictors of progression in atherosclerosis over 2 years in systemic*
657 *lupus erythematosus*. *Rheumatology (Oxford)*, 2011. **50**(11): p. 2071-9.
- 658 43. Kuklina, E.V., P.W. Yoon, and N.L. Keenan, *Trends in high levels of low-density*
659 *lipoprotein cholesterol in the United States, 1999-2006*. *JAMA*, 2009. **302**(19): p. 2104-
660 10.
- 661 44. Carroll, M.D., et al., *Total and high-density lipoprotein cholesterol in adults: National*
662 *Health and Nutrition Examination Survey, 2011-2012*. NCHS Data Brief, 2013(132): p.
663 1-8.
- 664 45. Mercado, C., et al., *Prevalence of Cholesterol Treatment Eligibility and Medication Use*
665 *Among Adults--United States, 2005-2012*. *MMWR Morb Mortal Wkly Rep*, 2015.
666 **64**(47): p. 1305-11.
- 667 46. Nelson, A.J., et al., *Use of Lipid-, Blood Pressure-, and Glucose-Lowering*
668 *Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular*
669 *Disease*. *JAMA Netw Open*, 2022. **5**(2): p. e2148030.
- 670 47. Stone, N.J., *Treating Severe Hypercholesterolemia-If Not Now, When?* *JAMA Cardiol*,
671 2022. **7**(2): p. 128-129.
- 672 48. Yoon, S.S., et al., *Trends in blood pressure among adults with hypertension: United*
673 *States, 2003 to 2012*. *Hypertension*, 2015. **65**(1): p. 54-61.
- 674 49. Ciemins, E.L., et al., *Application of a Tool to Identify Undiagnosed Hypertension -*
675 *United States, 2016*. *MMWR Morb Mortal Wkly Rep*, 2018. **67**(29): p. 798-802.
- 676 50. Kazemian, P., et al., *Evaluation of the Cascade of Diabetes Care in the United States,*
677 *2005-2016*. *JAMA Intern Med*, 2019. **179**(10): p. 1376-1385.
- 678 51. Fang, M., et al., *Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018*. *N*
679 *Engl J Med*, 2021. **384**(23): p. 2219-2228.
- 680 52. Wood, F.A., et al., *N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side*
681 *Effects*. *N Engl J Med*, 2020. **383**(22): p. 2182-2184.
- 682 53. Mach, F., et al., *2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid*
683 *modification to reduce cardiovascular risk*. *Eur Heart J*, 2020. **41**(1): p. 111-188.
- 684 54. Ference, B.A., *Interpreting the Clinical Implications of Drug-Target Mendelian*
685 *Randomization Studies*. *J Am Coll Cardiol*, 2022. **80**(7): p. 663-665.


- 686 55. Sivakumaran, J., et al., *Assessment of cardiovascular risk tools as predictors of*
687 *cardiovascular disease events in systemic lupus erythematosus*. *Lupus Sci Med*, 2021.
688 **8**(1).
- 689 56. Urowitz, M.B., et al., *Modified Framingham Risk Factor Score for Systemic Lupus*
690 *Erythematosus*. *J Rheumatol*, 2016. **43**(5): p. 875-9.
- 691 57. Zhu, L., et al., *Assessing the validity of QRISK3 in predicting cardiovascular events in*
692 *systemic lupus erythematosus*. *Lupus Sci Med*, 2022. **9**(1).
- 693 58. Quevedo-Abeledo, J.C., et al., *QRISK3 relation to carotid plaque is higher than that of*
694 *score in patients with systemic lupus erythematosus*. *Rheumatology (Oxford)*, 2022.
695 **61**(4): p. 1408-1416.
- 696 59. Sniderman, A.D., et al., *Apolipoprotein B Particles and Cardiovascular Disease: A*
697 *Narrative Review*. *JAMA Cardiol*, 2019. **4**(12): p. 1287-1295.
- 698 60. The Global BMI Mortality Collaboration, *Body-mass index and all-cause mortality:*
699 *individual-participant-data meta-analysis of 239 prospective studies in four continents*.
700 *Lancet*, 2016. **388**(10046): 776-86.
701
702

703 **Figures and Tables**


704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748

Figure 1. Assessment and management of plasma low-density lipoprotein cholesterol (LDLc) concentrations in the LE-ASCVD Study Cohort. **Panel A:** Classification of Study Cohort patients into the four categories of ASCVD event risk defined by the newly proposed guidelines of Keyes et al. for lupus patients.^[1] Also indicated are numbers of patients with LDLc levels above (red) or within (green) the newly proposed goals for each risk category. Patients without an available LDLc value are indicated in blue. **Panel B:** Absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic charts of patients classified into each of the four newly proposed categories of ASCVD event risk for lupus patients and whose most recent plasma LDLc levels were above the newly proposed goals; these are the patients indicated in red in panel 1A. **Panel C:** Estimated risk of an ASCVD event in the next 10 years (“10-year ASCVD event risk”) by the online ACC Risk Estimator Plus and absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic chart. Patients are grouped according to the cut-offs for estimated 10-year ASCVD event risk from the ACC/AHA guidelines for primary prevention of cardiovascular disease in the general population (0.0-4.9%, 5.0-7.4%, &c.).^[25] As noted in the Supplementary Methods, patients below age 40 years without clinically evident ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus (n=47/370) were scaled up to 40, and patients above age 79 years without clinically evident ASCVD (n=13/370) were scaled down to 79. Data are presented with these additional patients included (here) or presented separately in their own columns (Supplementary Figure S1C). Also shown here are data for patients with clinically evident ASCVD (meaning secondary prevention, for which the ACC ASCVD Risk Estimator Plus does not apply), as well as data for patients with no clinically evident ASCVD but insufficient information in the electronic chart for the ACC Risk Estimator (rightmost column). At the top of each column in panels A-C is indicated the total number of patients represented by that column. Numbers of patients represented by each tinted portion of each column are also given.


749
750
751



752
753
754
755
756
757
758




759
760
761
762
763




764
765
766
767
768

769 **Figure 2.** Assessment and management of several exacerbators and an additional causative agent
770 of ASCVD event risk in the LE-ASCVD Study Cohort. Panel A: Prevalence and management of
771 hypertension. Under-treated or untreated hypertension was defined by a systolic blood pressure
772 (BP) ≥ 130 and/or a diastolic BP ≥ 80 mm Hg, indicated here as “BP $\geq 130/80$ mm Hg”. Red
773 indicates patients with no record of an active prescription for an anti-hypertensive medication in
774 the electronic chart; green indicates patients on at least one anti-hypertensive medication. Panel
775 B: Prevalence and management of tobacco smoking. Red indicates patients with no chart
776 documentation of either smoking cessation counseling or a referral to a smoking cessation clinic;
777 green indicates patients with a record of one or both of these interventions. Data from never-
778 smokers are also shown (blue). Panel C: Assessment, or not (red), of glycated hemoglobin
779 (HbA_{1c}) values for patients stratified by obesity and/or glucocorticoid (GC) use, two common
780 factors in lupus patients that impair glycemic control. Diabetes was defined as in Table 1 as
781 chart-diagnosed or the most recent HbA_{1c} was $\geq 6.5\%$; here, yellow indicates diabetes and at least
782 one HbA_{1c} value on the chart. Five patients had a diagnosis of diabetes on their charts but no
783 available HbA_{1c} value; these patients are included within the red portions of the columns here.
784 Prediabetes (blue) was defined as chart-diagnosed or the most recent HbA_{1c} was 5.7-6.4%,
785 without a diagnosis of overt diabetes on the chart. Green indicates patients with at least one
786 HbA_{1c} value on the chart and no indication of either prediabetes or diabetes. Panel D:
787 Management of prediabetes and diabetes in the LE-ASCVD Study Cohort. For prediabetes,
788 well-managed (green) was defined here as documentation in the chart of lifestyle counseling
789 and/or an active prescription for metformin. For diabetes, well-managed (green) was defined
790 here as the most recent HbA_{1c} $\leq 7\%$.^[36-40] Red indicates not well-managed by these definitions.
791 Yellow in this panel indicates a diagnosis of diabetes but no available HbA_{1c} value on the chart.
792 Panel E: Assessment, or not (red), of plasma triglyceride (TG) concentrations for patients
793 stratified by obesity and/or GC use, two common factors in lupus patients that can elevate
794 plasma TGs. Most recent plasma TG values are classified as very high (≥ 500 mg/dl, yellow),
795 high (200-499 mg/dl, blue), or < 200 mg/dl (green).
796




797

798




799
800



801



802
803




804
805
806
807

808 **Figure 3.** Three systems to estimate the risk of a future ASCVD event for individual patients
809 within the LE-ASCVD Study Cohort. The three system were the ASCVD event risk categories
810 defined by Keyes et al. for LE patients (reference^[1] and Fig 1A); and numerical estimates of 10-
811 year ASCVD event risk generated by two widely used online calculators: QRisk3 (y-axis) versus
812 the ACC ASCVD Risk Estimator Plus (x-axis). Data are shown for the subset of patients in the
813 Study Cohort for whom both online calculators could be used, meaning no clinically evident
814 ASCVD (primary prevention) and sufficient data in the electronic charts to allow use of these
815 online tools. Data are presented with (here and in Supplementary Figure S2A,B; n=254) and
816 without (Supplementary Figure S2C,D; n=194) age-scaling for the ASCVD Risk Estimator Plus.
817 Panel A: Three estimates of ASCVD event risk for each of the 254 eligible LE patients. Each
818 dot represents an individual patient. Blue dots indicate patients classified at “High Risk”
819 (n=41/254), and yellow dots indicate patients classified at “Very High Risk” (n=213/254)
820 according to Keyes et al. For the two calculators, the horizontal and vertical dashed gray lines
821 indicate the key cut-off of 7.5% estimated 10-year ASCVD event risk from the ACC/AHA
822 guidelines for primary prevention of cardiovascular disease in the general population.^[25]
823 Pearson’s linear correlation was used to test the statistical relationship between the two
824 numerical estimates of 10-year ASCVD event risk, and the calculated regression line is indicated
825 in dashed red with key parameters given on the right. Panel B: Clinically meaningful agreement
826 (green) and discordance (red, white) amongst the three systems for estimating the risk of a future
827 ASCVD event for individual patients in the LE-ASCVD Study Cohort. The two pie charts
828 tabulate LE patients at “High Risk” as defined by Keyes et al. (n=41/254) and at “Very High
829 Risk” (n=213/254). Green indicates clinically meaningful agreement, defined here as
830 classification of an LE patient into the “High Risk” or “Very High Risk” categories of Keyes et
831 al., with estimates of 10-year ASCVD event risk $\geq 7.5\%$ from both of the online calculators. Red
832 indicates clinically significant discordance between the two online calculators, meaning one
833 estimate of 10-year ASCVD event risk $< 7.5\%$ but the other $\geq 7.5\%$ for the same LE patient.
834 White indicates discordance between Keyes et al. versus both of the online risk estimators, i.e.,
835 these patients are at High or Very High Risk according to Keyes et al., yet both online
836 calculators gave estimates of 10-year ASCVD event risk $< 7.5\%$. Numbers of patients
837 represented by each portion of each pie chart are given in the small filled black rectangles.

838
839
840
841
842
843
844
845
846
847
848
849
850


A



851
852
853
854
855
856
857
858
859
860
861
862
863
864


B

High Risk (n=41)




865

Very High Risk (n=213)



866
867

868 **Figure 4.** Kaplan-Meier curve of event-free survival since enrollment in the LE-ASCVD Study
 869 Cohort. An event was defined as a patient's first documented major adverse atherosclerotic
 870 cardiovascular event (MAACE) after enrollment. Displayed are median event-free survival rates
 871 over time (solid black stepped curve) with 95% confidence intervals (dashed curves). Following
 872 our definition, the 17 MAACE that were documented before enrollment are not shown on this
 873 graph. All patients in the LE-ASCVD Study Cohort were included in this survival curve. The
 874 actual documented 10-year ASCVD event rate in our Study Cohort was calculated as one minus
 875 the event-free survival rate of 0.777 (95% CI 0.726, 0.831) at the 10-year time point, which is
 876 highlighted by the thin vertical gray line.
 877



878
 879
 880
 881

882 **Table 1.** Demographics and other characteristics of the LE-ASCVD Study Cohort.
 883 Here and elsewhere, categorical parameters are given as n (%). Continuous variables are given as
 884 mean±SD, if normally distributed, or as median (interquartile range, IQR), if non-normally
 885 distributed.

Category	Parameter	Value	n in LE-ASCVD Study Cohort or subgroup
Demographics			
	Female	305 (82.4%)	370 (entire LE-ASCVD Study Cohort)
	White	190 (51.4%)	370
	Black	141 (38.1%)	370
	Asian	15 (4.1%)	370
	Hispanic	17 (4.6%)	370
Clinical course and care in the Cohort			
	Age at enrollment into the Cohort	47.1±14.9 years	370
	Age as of 2021	54.8±15.9 years	370
	Length of time since enrollment into the Cohort	7.7±4.5 years	370
	Extreme Risk for future ASCVD events*	82 (22.2%)	370
	CLE patients with concurrent SLE	190 (51.4%)	370
	History of lupus nephritis	42 (11.4%)	370
	History of CKD stage 3 or 4‡	37 (10.0%)	370
	Hypertension§	266 (71.9%)	370
	Former Smokers	109 (29.5%)	370
	Current Smokers	63 (17.0%)	370
	Most recent BMI	28.4±7.1 kg/m ²	346 (subgroup with at least one set of simultaneous height and weight measurements)
	Obese (BMI ≥30.0 kg/m ²)	116 (33.5%)	346
	Prediabetes**	67 (18.1%)	370
	Diabetes mellitus**	39 (10.5%)	370
Provider Data			

	Patients with a listed PCP in the chart	336 (90.8%)	370
	Patients with documented PCP visit in the chart	279 (75.4%)	370

886 BMI, body mass index; PCP, primary care provider.

887 *Extreme ASCVD event risk was defined by Keyes et al. 2021 as “Patients with LE ... and
888 clinically evident ASCVD”, i.e., secondary prevention in the context of LE.^[1]

889 ‡An additional five (1.4%) patients in the LE-ASCVD Study Cohort were in CKD stage 5,
890 meaning an eGFR below 15 ml/min/1.73m².

891 §Hypertension was defined following the recently updated joint guidelines from the ACC and
892 the American Heart Association (AHA),^[34] here based on averaged blood pressure readings
893 from the most recent year of follow-up, plus the list of active prescriptions in the electronic
894 charts. Three hundred forty-one patients (92.3% of the LE-ASCVD Cohort) had two or more
895 readings in their electronic charts in this period; 28 patients (7.6%) had only one reading; and
896 1 patient had no available blood pressure value in the most recent year.

897 **Following criteria from the American Diabetes Association (ADA), HbA_{1c} values of 5.7-6.4%
898 indicate prediabetes, and HbA_{1c} ≥6.5% is diagnostic for diabetes mellitus.^[34] Accordingly,
899 prediabetes was defined here as chart-diagnosed or the most recent HbA_{1c} was 5.7-6.4%,
900 without a diagnosis of overt diabetes on the chart. Diabetes was defined as chart-diagnosed
901 or the most recent HbA_{1c} was ≥6.5%. The most recent HbA_{1c} value for some patients with a
902 diagnosis of diabetes mellitus was below 6.5%; we still classified them under diabetes unless
903 a clinician had marked the diagnosis on the chart as resolved or in remission.^[34-38]

904
905
906

907 **Table 2.** Types, numbers, and timing of major adverse atherosclerotic cardiovascular events
 908 (MAACE) documented in the LE-ASCVD Study Cohort.
 909

Type of MAACE	Number affected (% of the 370 patients in the LE-ASCVD Study Cohort)*	Time from enrollment to event in years, given as median (IQR); and number of events (n)‡
Atherosclerotic myocardial infarction (MI)	14 (3.8%)	6.5 (4-11); n=12
Newly diagnosed ischemic heart disease other than MI	31 (8.4%)	8.0 (5-13); n=25
Atherosclerotic (non-embolic) ischemic stroke or transient cerebrovascular ischemic attack	15 (4.1%)	11.0 (7-14); n=10
Newly diagnosed symptomatic peripheral vascular disease (PVD)	3 (0.8%)	5.0; n=3
Hospitalization for chest pain, shortness of breath, or palpitations with suspicion of ischemic origin	29 (7.8%)	7.0 (5-8); n=28
Any MAACE	82 (22.2%)	7.0 (5-11); n=65

910 *Any patient who experienced two or more MAACE before and since enrollment was counted
 911 only once in any given row but was counted in two or more rows if the types of MAACE
 912 differed. Thus, the sum of the numbers of patients affected by each specific type of MAACE
 913 (92 total, 78 since enrollment) is slightly larger than the number of patients affected by any
 914 MAACE (82 total, 65 since enrollment).

915 ‡Time and n in this column exclude the 17 events that were documented in lupus patients before
 916 their enrollment in the LE-ASCVD Study Cohort. IQR ranges are given for each type of
 917 MAACE only if n ≥6.
 918